pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.4k
4.4k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
12085C | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12085C | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12085C | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12086D | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12090H | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12094M | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12095N | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12095N | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12095N | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12099T | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment in a patient weighing at least 30 kg | 14088 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12102Y | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12105D | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12105D | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12105D | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12209N | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12209N | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1220F | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1220F | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1220F | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1220F | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12217B | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12217B | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12217B | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12217B | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1221G | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
1221G | Abatacept | Orencia | Injection 125 mg in 1 mL single dose pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12297F | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12297F | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12307R | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12321L | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12321L | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12321L | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12326R | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12326R | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12326R | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12326R | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12327T | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12328W | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12329X | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12329X | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12329X | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12329X | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12335F | Adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,404 | 2,025 | MARCH |
12348X | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12348X | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12348X | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12348X | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12349Y | Adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 4,404 | 2,025 | MARCH |
12355G | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12355G | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12355G | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12355G | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12361N | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
12362P | Adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,404 | 2,025 | MARCH |
Subsets and Splits